New drug strategies, such as combining BRAF or MEK inhibitors with pan-PI3K inhibitors, are beginning to show pre-clinical promise in thyroid cancer (Nagarajah et al., 2016). This evidence concerns the gene MAP2K7 and thyroid cancer.